SCHEMBL1586959

SCHEMBL1586959

OCc1ccc(CN2CCC3(C=Cc4ccccc43)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MCHR2 Q969V1 9/20 0.61
MCHR1 Q99705 1/20 0.57
FFAR1 O14842 4/20 0.52
SIGMAR1 Q99720 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7382222 0.89 MCHR2 (0.62) MCHR2MCHR1FFAR1SIGMAR1
SCHEMBL4408710 0.86 MCHR2 (0.61) MCHR2MCHR1FFAR1SIGMAR1
SCHEMBL1587467 0.86 MCHR2 (0.61) MCHR2MCHR1FFAR1SIGMAR1
SCHEMBL13518801 0.86 FFAR1 (0.58) MCHR2MCHR1FFAR1
SCHEMBL13518904 0.83 FFAR1 (0.58) MCHR2MCHR1FFAR1
SCHEMBL4233076 0.83 SIGMAR1 (0.58) MCHR2MCHR1FFAR1SIGMAR1
SCHEMBL15160320 0.83 MCHR2 (0.57) MCHR2MCHR1FFAR1SIGMAR1
SCHEMBL3812702 0.82 MCHR2 (0.65) MCHR2MCHR1FFAR1
SCHEMBL13518939 0.81 FFAR1 (0.57) MCHR2MCHR1FFAR1
SCHEMBL13519096 0.81 MCHR2 (0.59) MCHR2MCHR1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150266839-A1 CYCLIC AMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-09-24 US disclosed
US-20150225392-A1 CYCLIC AMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-9072758-B2 Cyclic amide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-07-07 US disclosed
US-9040525-B2 Cyclic amide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-05-26 US disclosed
US-8765752-B2 3-hydroxyisothiazole 1-oxide derivatives MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-07-01 US disclosed
EP-2703394-A1 NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE Mochida Pharmaceutical Co., Ltd. (JP) 2014-03-05 EP disclosed
EP-2703393-A1 CYCLIC AMIDE DERIVATIVE Mochida Pharmaceutical Co., Ltd. (JP) 2014-03-05 EP disclosed
US-20140057871-A1 CYCLIC AMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-02-27 US disclosed
US-8629102-B2 3-hydroxyisothiazole 1-oxide derivatives MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-01-14 US disclosed
US-8557766-B2 3-hydroxyisothiazole 1-oxide derivatives MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2013-10-15 US disclosed
US-20130210721-A1 NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2013-08-15 US disclosed
US-20130203739-A1 CYCLIC AMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2013-08-08 US disclosed
US-8383642-B2 Spiropiperidine compounds ELI LILLY AND COMPANY (US) 2013-02-26 US disclosed
US-8383642-B2 Spiropiperidine compounds ELI LILLY AND COMPANY (US) 2013-02-26 US disclosed
US-8383642-B2 Spiropiperidine compounds ELI LILLY AND COMPANY (US) 2013-02-26 US disclosed
US-20120277150-A1 NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2012-11-01 US disclosed
US-20110092531-A1 Novel Spiropiperidine Compounds ELI LILLY AND COMPANY (US) 2011-04-21 US disclosed
US-20110092531-A1 Novel Spiropiperidine Compounds ELI LILLY AND COMPANY (US) 2011-04-21 US disclosed
US-20110092531-A1 Novel Spiropiperidine Compounds ELI LILLY AND COMPANY (US) 2011-04-21 US disclosed
WO-2011046851-A1 SPIROPIPERIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF FOR TREATING DIABETES ELI LILLY AND COMPANY (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092531-A1 Novel Spiropiperidine Compounds REN, SLC5A1, SLC5A2 MCHR2 2179/4885MCHR1 2417/4885FFAR1 910/4885
US-20150266839-A1 CYCLIC AMIDE DERIVATIVE GPR119, NR0B1, NR4A1 MCHR2 794/4885MCHR1 471/4885FFAR1 27/4885
US-20140057871-A1 CYCLIC AMIDE DERIVATIVE GPR119, NR0B1, NR4A1 MCHR2 834/4885MCHR1 486/4885FFAR1 29/4885
US-20130210721-A1 NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES GPR119, GPR27, GPR65 MCHR2 442/4885MCHR1 300/4885FFAR1 29/4885
US-20150225392-A1 CYCLIC AMIDE DERIVATIVE GPR119, NR0B1, NR2C2 MCHR2 473/4885MCHR1 321/4885FFAR1 25/4885
US-20120277150-A1 NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE GPR119, GPR27, GPR65 MCHR2 419/4885MCHR1 289/4885FFAR1 29/4885
US-20130203739-A1 CYCLIC AMIDE DERIVATIVE GPR119, NR0B1, NR2C2 MCHR2 493/4885MCHR1 338/4885FFAR1 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.